A Phase I/II, Randomized, Double-blind, Placebo, and Active Controlled Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JHM03 in Subjects With Moderate to Severe Glabellar Lines
Sponsor: JHM BioPharma (Tonghua) Co. , Ltd.
A PHASE1/PHASE2 clinical study on Moderate to Severe Glabellar Lines, this trial is completed. The trial is conducted by JHM BioPharma (Tonghua) Co. , Ltd. and has accumulated 5 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
May 2025 — Present [monthly]
Completed PHASE1/PHASE2
Status: Recruiting → Completed
-
Sep 2024 — May 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2024 — May 2024 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Jan 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- JHM BioPharma (Tonghua) Co. , Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .